A Study of LY2835219 in Participants With Cancer

Completed · Phase 1

Conditions studied: Neoplasm, Neoplasm Metastasis

In brief

The purpose of this study is to assess how the body handles Abemaciclib when it is given with another drug called clarithromycin. The study doctor will measure the amount of Abemaciclib that is absorbed into the blood stream and the time that it takes to remove Abemaciclib from the body. The safety and tolerability of these drugs will be studied. Each participant will complete 2 study periods in fixed order. After screening, Period 1 will last approximately 8 days and Period 2 will last approximately 15 days. Participants who complete Period 2 may continue to receive Abemaciclib in 28-day cycles until discontinuation criteria are met.

Key facts

Study ID

NCT02117648

Run by

Eli Lilly and Company

People needed

26

Starts

2014-04-01

Expected to finish

2015-08-01

Last updated by the study team

2019-01-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have histological or cytological evidence of cancer (solid tumors) that is advanced and/or metastatic
• Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale

You may not qualify if…

• No symptomatic central nervous system (CNS) malignancy or metastasis

Where it is running

• Accelerated Comm. Oncology Research Network (ACORN) — Memphis, Tennessee, United States
• The West Clinic — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.